secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cellectar Biosciences, Inc. (CLRB)
CIK:        0001279704
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001104659-24-088606
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cellectar reports Q2 2024 cash of $25.9M; pivotal WM trial shows 80% ORR, exceeding primary endpoint
--------------------------------------------------------------------------------

- Cash and equivalents $25.9M as of June 30, 2024, up from $9.6M at Dec 31, 2023. Net cash used in ops Q2 2024 was $14.1M.
- R&D expense $8.2M (Q2 2024) vs $6.3M (Q2 2023); G&A $6.4M vs $2.0M.
- CLOVER WaM study: 80% ORR, 56.4% MRR exceeded primary endpoint of 20% MRR; median prior lines of therapy was 4.
- NDA filing for iopofosine I 131 in WM planned for Q4 2024; accelerated 6-month review; potential 2025 launch.
- Raised $19.4M in July 2024; cash runway into Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1279704/000110465924088606/0001104659-24-088606-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1279704/000110465924088606/tm2421529d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-088606

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer